Abstract: All multiple myeloma cell lines examined showed constitutively active I?B kinase (IKK), I?B? phosphorylation and constitutively active NF-?B. Curcumin, a chemopreventive agent, suppressed constitutive I?B? phosphorylation through inhibition of IKK activity and downregulated NF-?B. Curcumin also downregulated expression of NF-?B-regulated gene products such as I?B?, Bcl-2, Bcl-xL, cyclin D1 and interleukin-6. Consequently, curcumin suppressed multiple myeloma cell proliferation and arrested cells at the G1/S phase of the cell cycle. Curcumin also induced apoptosis and chemosensitivity to vincristine. Overall, results presented herein provide a molecular basis for the treatment of multiple myeloma patients with this pharmacologically safe agent.
Abstract: This invention relates to methods for using benzopyranones, or their pharmaceutically acceptable salts, for treating or preventing a primary brain cancer or a brain metastasis. The benzopyranones have the formula: wherein R1, R2, R3, n and p are as defined herein.
Abstract: Treatment with a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases.
Type:
Grant
Filed:
July 10, 2003
Date of Patent:
November 28, 2006
Assignee:
Pharmacia Corporation
Inventors:
Susan A Gregory, Peter G. Isakson, Gary Anderson
Abstract: There is provided a method of promoting neurogenesis by administering a therapeutic amount of a nitric oxide donor compound to a patient in need of neurogenesis promotion. Also provided is a compound for providing neurogenesis having an effective amount of a nitric oxide donor sufficient to promote neurogenesis. A nitric oxide compound for promoting neurogenesis is also provided. Further, a method of augmenting the production of brain cells and facilitating cellular structural and receptor changes by administering an effective amount of a nitric oxide donor compound to a site in need of augmentation is provided. There is provided method of increasing both neurological and cognitive function by administering an effective amount of a nitric oxide donor compound to a patient.
Abstract: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Type:
Grant
Filed:
July 5, 2002
Date of Patent:
October 24, 2006
Assignee:
Merck & Co., Inc.
Inventors:
Scott D Edmondson, Michael H. Fisher, Dooseop Kim, Malcolm Maccoss, Emma R. Parmee, Ann E Weber, Jinyou Xu
Abstract: This invention is directed to a method for preventing or treating bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1–C4 alkyl; wherein C1–C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1–C4 alkyl, C1–C4 alkoxy, amino, nitro and cyano).
Type:
Grant
Filed:
February 21, 2002
Date of Patent:
October 17, 2006
Inventors:
Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman, Yong Moon Choi, Robert Gordon
Abstract: Methods and therapeutic compounds for treating pain, mitigating inflammation, effecting analgesia and/or effecting sedation in a subject are described. A subject is administered an effective amount of a therapeutic compound which is a nitrate ester. Novel pharmaceutical compositions are also described.
Type:
Grant
Filed:
December 29, 1999
Date of Patent:
October 3, 2006
Assignee:
Queen's University at Kingston
Inventors:
Gregory R. J. Thatcher, Brian M. Bennett, James N. Reynolds, Khem Jhamandas
Abstract: The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA. Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in combination with drugs that induce DNA breaks such as cisplatin and mitomycin C. These compounds have a synergistic effect when used in combination for inhibiting tumour growth. The invention includes pharmaceutical compositions for inhibiting tumour growth comprising a compound that inhibits endo-exonuclease activity. These pharmaceutical compositions preferably include compounds that induce DNA breaks. The invention includes methods of treating cancer with these pharmaceutical compositions and uses of these compositions to treat cancer. The preferred compounds that inhibit the activity of endo-exonuclease have low toxicity. One such compound is pentamidine.
Type:
Grant
Filed:
November 16, 2000
Date of Patent:
October 3, 2006
Assignee:
Onocozyme Pharma, Inc.
Inventors:
Terry Chow, Chiaoli Yeh, David Griller, Leonard Yuen
Abstract: Antimicrobial compositions containing a carboxylic acid, for example, a fatty acid, and a carrier medium including a freezing point depressant are disclosed. The compositions can be formulated for use as a teat dip, for use on milk producing animals. In one particularly advantageous embodiment, a composition is formulated as a teat dip and includes suitable emollients, skin conditioners and lubricants.
Type:
Grant
Filed:
October 2, 2000
Date of Patent:
September 19, 2006
Assignee:
Ecolab, Inc.
Inventors:
Francis Lawrence Richter, Duane Joseph Reinhardt
Abstract: The present invention provides methods of inhibiting metastasis of a tumor and methods of treating a tumor using a combination of an inhibitor of the activation of nuclear factor NF-?B and a cancer chemotherapeutic agent. In one embodiment of the present invention, combination of curcumin and paclitaxel (taxol) can be used to treat and inhibit metastasis of breast tumor.
Abstract: The invention provides methods and compositions for treating erectile dysfunction. The methods include the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a vasoactive prostaglandin composition of a semi-solid consistency. The composition comprises a vasoactive prostaglandin, a penetration enhancer, a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N-substituted amino)-alkanoate ester, a (N-substituted amino)-alkanol alkanoate, or a mixture of these enhancers. The lipophilic compound may be an aliphatic C1 to C8 alcohol, aliphatic C2 to C30 ester, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system providing a buffered pH value for said composition in the range of about 3 to about 7.4.
Type:
Grant
Filed:
September 6, 2002
Date of Patent:
September 12, 2006
Assignee:
NexMed Holdings, Inc.
Inventors:
James L. Yeager, Nadir Büyüktimkin, Servet Büyüktimkin
Abstract: A pharmaceutical composition in a form of an orally deliverable liquid comprises water having in solution therein a pharmaceutically acceptable water-soluble salt of a tolterodine related compound at a therapeutically effective concentration in the composition. The composition has a pH of about 2 to about 6 and further comprises a sweetening agent and an antimicrobial agent at a concentration that is antimicrobially effective at the pH of the composition. The composition is useful for treating a muscarinic receptor mediated disorder, more particularly overactive bladder, in a subject by orally administering to the subject a therapeutically effective amount of the composition.
Type:
Grant
Filed:
August 25, 2003
Date of Patent:
September 5, 2006
Assignee:
Pharmacia & UpJohn Company
Inventors:
Joseph P. Reo, Kathryn M. Kienle, Jennifer K. Fredrickson
Abstract: Macromolecules in the shape of three-dimensional kites, barbells, and other shapes are disclosed. The shaped macromolecules are prepared the reaction of one or more dendritic polymers and a linear polymer. The kite-shaped macromolecules are dendritic polymers attached at either their focal points or at an outer to a long carbon chain group. The barbell macromolecules have dendritic polymers at either end of the molecule, which polymers are connected together through the focal points of each by a suitable connecting substituent such as a linear polymer. The shaped macromolecules are used in specialty medical and technological applications including such as drug delivery agents, imaging materials, molecular devices, thin film devices, surface modifiers, transport agents, compatibilizers, rheology control agents, molecular ball bearings, molecular dipoles, non-linear optical materials, medical imaging agents, membrane and cell modifiers, complexing agents, adhesives, interface strengthening agents, and the like.
Type:
Grant
Filed:
April 14, 1995
Date of Patent:
September 5, 2006
Inventors:
Jean M. J. Frechet, Craig J. Hawker, Karen Wooley
Abstract: The present invention provides a method for preventing and treating gastrointestinal diseases such as dyspepsia, irritable bowel disease and chemotherapy-associated nausea by administering an antagonist or partial agonist of 5HT1a receptors.
Type:
Grant
Filed:
October 13, 2000
Date of Patent:
August 29, 2006
Assignee:
Athpharma Limited
Inventors:
Timothy G. Dinan, Patrick W. N. Keeling
Abstract: The invention is directed to the use of imatinib mesylate for treating polycythemia vera. Imatinib mesylate is surprisingly effective at controlling the symptoms of polycythemia vera and reducing the need for phlebotomy.
Abstract: The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.
Type:
Grant
Filed:
March 24, 2005
Date of Patent:
August 15, 2006
Assignee:
Novartis AG
Inventors:
Terence O'Reilly, Markus Wartmann, Manuel Litchman, Pamela Cohen
Abstract: A stabilized amrubicin hydrochloride composition which comprises 3 to 8 wt. % water and 92 to 97 wt. % amrubicin hydrochloride; and a method of storing amrubicin hydrochloride.
Type:
Grant
Filed:
October 22, 2002
Date of Patent:
August 15, 2006
Assignees:
Sumitomo Chemical Company, Limited, Dainippon Sumitomo Pharma Co., Ltd.
Inventors:
Kazuhiko Takahashi, Koji Fujimoto, Yasuko Yamauchi, Takanori Okahashi
Abstract: The invention provides a composition for attenuating neovascularization and treating malignancies, including a pharmaceutically effective amount of a compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy carbonyl; as active ingredient therein, in combination with a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
December 20, 2000
Date of Patent:
April 17, 2007
Assignees:
Hadasit Medical Research Services and Development Company Ltd., Agricultural Research Organization Ministry of Agriculture
Inventors:
Mark Pines, Israel Vlodavsky, Arnon Nagler, Hua-Quan Mian
Abstract: The present invention discloses a method for the prevention of atherosclerosis, its genesis, progression and restenosis in human patients undergoing treatments for arterial lesions such as PTA or atherectomy, and which may be accompanied by stent implantation. Further, the treatment method disclosed has applicability in all stages of atherosclerosis in which monocytes play a role. The compound utilized in the present method as the active agent is a 2-halo-2?-deoxyadenosine such as 2-chloro-deoxyadenosine (2-CdA). The treatment method of the present invention includes the administration of 14 doses of 2-CdA in the amount of 0.12 mg/kg. One dose is given intravenously before the coronary intervention, another is given intravenously after the intervention and the remaining twelve doses are given subcutaneously at weekly intervals over a subsequent three month period.